New drug combo shows promise for Tough-to-Treat GI cancers

NCT ID NCT06428409

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink. About 220 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (MK-2870), a biologic drug given by IV infusion, sometimes combined with chemotherapy drugs (fluorouracil, leucovorin) and rescue medications.
What this could lead to: If successful, this could provide a new treatment option for people with advanced gastrointestinal cancers that have not responded to prior therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms colorectal cancer colorectal neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER COLORECTAL CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ASST Grande Ospedale Metropolitano Niguarda ( Site 0102)
RECRUITING

Milan, Lombardy, 20162, Italy
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 0242)
COMPLETED

Ankara, 06800, Turkey (Türkiye)
Asan Medical Center ( Site 0163)
RECRUITING

Seoul, 05505, South Korea
Barts Health NHS Trust ( Site 0263)
RECRUITING

London, England, E1 1RD, United Kingdom
Beijing Cancer hospital-Digestive Oncology ( Site 0061)
RECRUITING

Beijing, Beijing Municipality, 100142, China
Bradfordhill-Clinical Area ( Site 0047)
RECRUITING

Santiago, Region M. de Santiago, 8420383, Chile
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
RECRUITING

Montreal, Quebec, H2X 0A9, Canada
Chang Gung Medical Foundation-Linkou Branch ( Site 0222)
RECRUITING

Taoyuan, 33305, Taiwan
China Medical University Hospital ( Site 0223)
RECRUITING

Taichung, 404332, Taiwan
Clínica UC San Carlos de Apoquindo ( Site 0043)
RECRUITING

Santiago, Region M. de Santiago, 7620002, Chile
Epworth Freemasons ( Site 0005)
RECRUITING

East Melbourne, Victoria, 3002, Australia
FALP-UIDO ( Site 0041)
RECRUITING

Providencia, Region M. de Santiago, 7500921, Chile
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0101)
RECRUITING

Milan, Lombardy, 20133, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0103)
RECRUITING

Roma, 00168, Italy
Frankston Hospital-Oncology and Haematology ( Site 0004)
RECRUITING

Frankston, Victoria, 3199, Australia
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 0183)
RECRUITING

Madrid, Madrid, Comunidad de, 28009, Spain
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0241)
COMPLETED

Ankara, 06230, Turkey (Türkiye)
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0181)
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario Central de Asturias-Medical Oncology ( Site 0182)
RECRUITING

Oviedo, Principality of Asturias, 33011, Spain
Hunan Cancer Hospital-intervention department ( Site 0066)
RECRUITING

Changsha, Hunan, 410013, China
Hôpitaux Universitaires de Genève (HUG) ( Site 0202)
RECRUITING

Geneva, Canton of Geneva, 1211, Switzerland
James Lind Centro de Investigacion del Cancer ( Site 0048)
RECRUITING

Temuco, Araucania, 4800827, Chile
Kanagawa Cancer Center ( Site 0122)
RECRUITING

Yokohama, Kanagawa, 241-8515, Japan
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324)
RECRUITING

New York, New York, 10016, United States
McGill University Health Centre ( Site 0023)
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Mount Sinai Cancer Center ( Site 0287)
RECRUITING

Miami Beach, Florida, 33140, United States
National Cancer Center Hospital East ( Site 0121)
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
National Cheng Kung University Hospital-Clinical Trial Center ( Site 0224)
RECRUITING

Tainan, 704, Taiwan
National Taiwan University Hospital-Oncology ( Site 0225)
RECRUITING

Taipei, 10002, Taiwan
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303)
COMPLETED

Marietta, Georgia, 30060, United States
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295)
RECRUITING

Roanoke, Virginia, 24014, United States
One Clinical Research ( Site 0002)
RECRUITING

Nedlands, Western Australia, 6009, Australia
Ospedale Regionale Bellinzona e Valli ( Site 0201)
RECRUITING

Bellinzona, Canton Ticino, 6500, Switzerland
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327)
RECRUITING

Mineola, New York, 11501, United States
Renji Hospital Shanghai Jiao Tong University School of Medicine-Oncology Department ( Site 0067)
RECRUITING

Shanghai, Shanghai Municipality, 200127, China
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 0001)
RECRUITING

Brisbane, Queensland, 4029, Australia
Royal Free Hospital ( Site 0262)
RECRUITING

London, England, NW3 2QG, United Kingdom
Samsung Medical Center ( Site 0162)
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital ( Site 0161)
RECRUITING

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System ( Site 0164)
RECRUITING

Seoul, 03722, South Korea
Sibley Memorial Hospital ( Site 0310)
RECRUITING

Washington D.C., District of Columbia, 20016, United States
Taipei Veterans General Hospital ( Site 0221)
RECRUITING

Taipei, 112, Taiwan
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 0063)
RECRUITING

Fuzhou, Fujian, 350025, China
The Ottawa Hospital Cancer Centre ( Site 0027)
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
UCLA ( Site 0317)
RECRUITING

Los Angeles, California, 90095, United States
University Hospital Coventry & Warwickshire ( Site 0266)
RECRUITING

Coventry, CV2 2DX, United Kingdom
University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293)
RECRUITING

Madison, Wisconsin, 53792, United States
University of Colorado Anschutz Medical Campus ( Site 0299)
RECRUITING

Aurora, Colorado, 80045, United States
University of Colorado Anschutz Medical Campus ( Site 0325)
RECRUITING

Aurora, Colorado, 80045, United States
University of Colorado Anschutz Medical Campus ( Site 0326)
RECRUITING

Aurora, Colorado, 80045, United States
University of Florida College of Medicine ( Site 0281)
RECRUITING

Gainesville, Florida, 32610, United States
University of Texas MD Anderson Cancer Center ( Site 0316)
RECRUITING

Houston, Texas, 77030, United States
West China Hospital, Sichuan University ( Site 0068)
RECRUITING

Chengdu, Sichuan, 610041, China
Westmead Hospital ( Site 0003)
RECRUITING

Westmead, New South Wales, 2145, Australia
Wuhan Union Hospital Cancer Center. ( Site 0064)
RECRUITING

Wuhan, Hubei, 430024, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.